Pharmaceutical company stocks were among the winners in early trading Wednesday as Republicans’ sweeping election victory eased concerns that Democrats would enact controls on drug prices. Eli Lilly and Co. shares jumped 4 percent.
The company's top-selling product, the insulin Humalog, saw U.S. sales by volume rise 10 percent in the third quarter. But because of rebates and other discounts, revenue dropped 14 percent.
Makers of insulin became the latest target for Sen. Bernie Sanders, who has been going after pharmaceutical companies one by one over the issue of high U.S. drug prices.
A champion for alternative scheduling to attract, retain and develop workers, Amy Judge-Prein focuses on regulatory and strategic aspects of the development of pharmaceuticals, medical devices and diagnostics.
In pursuit of the essence of Hoosier basketball, photographers Michael E. Keating and Chris Smith logged over 10,000 miles and visited 130 gyms across the state, taking more than 150,000 photos along the way.
For decades, the RCA brand has been associated with televisions and other consumer electronics. But it’s LED lighting that’s helping fuel growth for Indianapolis-based RCA Commercial Electronics.
Drugmakers including Eli Lilly and Co. are becoming increasingly vocal in fighting a California ballot proposition designed to bring down prices on prescription medicine.
Sales of Lilly's Humalog insulin, its top-selling product, fell 9 percent, to $641 million, offsetting gains by a stable of new drugs that is helping the company weather a blitz of patent expirations.
The new degree blends such disciplines as biostatistics, computer science and informatics to better understand issues related to health care cost and quality.
Eli Lilly and Co. is pledging $90 million over five years to improve access to treatment for diabetes, cancer and tuberculosis in developing countries—the latest push in its philanthropic strategy of building health care systems around the world and increasing the market for its prescription drugs.
The residents who sued sought to revoke the school’s property-tax exemption, in part because Princeton shares commercial royalties with faculty from a patent that Indianapolis-based Eli Lilly and Co. turned into the cancer drug Alimta.
For more than two years, Eli Lilly and Co. has pushed the message that the worst days are over and a brighter future is just around the corner. Now, finally, Wall Street is starting to believe.
The Indianapolis drugmaker's animal-health division is bulking up its companion-animal business by buying Boehringer Ingelheim International's U.S. feline, canine and rabies medications.
